Related Experiment Video
Updated: Jun 6, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Are we nearer to curing patients with MDS?
1Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, OH 44195, USA. sekerem@ccf.org
Abstract:
Myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic disorders derived from abnormal multipotent progenitor cells. They have been classified by the World Health Organization as myeloid neoplasms with several different subtypes based on morphology and cytogenetics. Because MDS was only recently recognized as a cancer, epidemiological data is tentative and incidence and prevalence will probably increase as reporting improves. Prognosis for MDS patients is calculated using the International Prognostic Scoring System, though this system is currently being revised by several groups. Therapy for MDS varies based on pathobiology, prognosis, and cytogenetics, such as the deletion of 5q. Treatment options range from supportive care, to disease-modifying chemotherapeutic agents, to stem cell transplantation, to therapies that may affect quality of life, improve survival, or even cure the disease.
More Related Videos
Related Concept Videos
Mismatch Repair
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
iPS Cell Differentiation
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Satellite Stem Cells and Muscular Dystrophy

